Key facts
| Price (PPV) | 106.70 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | losartanhydrochlorothiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA01 |
| Manufacturer | AFRIC-PHAR |
| Presentation | Boite de 28 |
| Nature | Médicament |
| Hospital price | 66.70 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement de l’hypertension artérielle essentielle chez les patients dont la pression artérielle n’est pas suffisamment contrôlée par le losartan ou l’hydrochlorothiazide en monothérapie.
Find an open pharmacy
On-call pharmacies near you
About Co-Tanzaar 50 mg / 12.5 mg
Co-Tanzaar 50 mg / 12.5 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by AFRIC-PHAR and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Co-Tanzaar 50 mg / 12.5 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Co-Tanzaar 50 mg / 12.5 mg
Answers to common questions from Moroccan patients about this drug.